These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 31745210)

  • 1. STING expression in monocyte-derived macrophages is associated with the progression of liver inflammation and fibrosis in patients with nonalcoholic fatty liver disease.
    Wang X; Rao H; Zhao J; Wee A; Li X; Fei R; Huang R; Wu C; Liu F; Wei L
    Lab Invest; 2020 Apr; 100(4):542-552. PubMed ID: 31745210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of STING Is Increased in Liver Tissues From Patients With NAFLD and Promotes Macrophage-Mediated Hepatic Inflammation and Fibrosis in Mice.
    Luo X; Li H; Ma L; Zhou J; Guo X; Woo SL; Pei Y; Knight LR; Deveau M; Chen Y; Qian X; Xiao X; Li Q; Chen X; Huo Y; McDaniel K; Francis H; Glaser S; Meng F; Alpini G; Wu C
    Gastroenterology; 2018 Dec; 155(6):1971-1984.e4. PubMed ID: 30213555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
    Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
    Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Adipose Tissue Inflammation With Histologic Severity of Nonalcoholic Fatty Liver Disease.
    du Plessis J; van Pelt J; Korf H; Mathieu C; van der Schueren B; Lannoo M; Oyen T; Topal B; Fetter G; Nayler S; van der Merwe T; Windmolders P; Van Gaal L; Verrijken A; Hubens G; Gericke M; Cassiman D; Francque S; Nevens F; van der Merwe S
    Gastroenterology; 2015 Sep; 149(3):635-48.e14. PubMed ID: 26028579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Macrophage heterogeneity role in NAFLD and NASH disease progression].
    Yang T; Wang X; Jiang LF; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2023 Jul; 31(7):770-775. PubMed ID: 37580264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crosstalk Between Liver Macrophages and Surrounding Cells in Nonalcoholic Steatohepatitis.
    Li H; Zhou Y; Wang H; Zhang M; Qiu P; Zhang M; Zhang R; Zhao Q; Liu J
    Front Immunol; 2020; 11():1169. PubMed ID: 32670278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. XBP1-mediated activation of the STING signalling pathway in macrophages contributes to liver fibrosis progression.
    Wang Q; Bu Q; Liu M; Zhang R; Gu J; Li L; Zhou J; Liang Y; Su W; Liu Z; Wang M; Lian Z; Lu L; Zhou H
    JHEP Rep; 2022 Nov; 4(11):100555. PubMed ID: 36185574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.
    Puengel T; Lefere S; Hundertmark J; Kohlhepp M; Penners C; Van de Velde F; Lapauw B; Hoorens A; Devisscher L; Geerts A; Boehm S; Zhao Q; Krupinski J; Charles ED; Zinker B; Tacke F
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2.
    Miura K; Yang L; van Rooijen N; Ohnishi H; Seki E
    Am J Physiol Gastrointest Liver Physiol; 2012 Jun; 302(11):G1310-21. PubMed ID: 22442158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.
    Rosso C; Kazankov K; Younes R; Esmaili S; Marietti M; Sacco M; Carli F; Gaggini M; Salomone F; Møller HJ; Abate ML; Vilstrup H; Gastaldelli A; George J; Grønbæk H; Bugianesi E
    J Hepatol; 2019 Nov; 71(5):1012-1021. PubMed ID: 31301321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
    Kleiner DE; Brunt EM; Wilson LA; Behling C; Guy C; Contos M; Cummings O; Yeh M; Gill R; Chalasani N; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Terrault N; Kowdley K; Loomba R; Belt P; Tonascia J; Lavine JE; Sanyal AJ;
    JAMA Netw Open; 2019 Oct; 2(10):e1912565. PubMed ID: 31584681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NLRP3 inflammasome activation is required for fibrosis development in NAFLD.
    Wree A; McGeough MD; Peña CA; Schlattjan M; Li H; Inzaugarat ME; Messer K; Canbay A; Hoffman HM; Feldstein AE
    J Mol Med (Berl); 2014 Oct; 92(10):1069-82. PubMed ID: 24861026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying a distinct fibrosis subset of NAFLD via molecular profiling and the involvement of profibrotic macrophages.
    He W; Huang Y; Shi X; Wang Q; Wu M; Li H; Liu Q; Zhang X; Huang C; Li X
    J Transl Med; 2023 Jul; 21(1):448. PubMed ID: 37415134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis.
    Zou A; Magee N; Deng F; Lehn S; Zhong C; Zhang Y
    J Biol Chem; 2018 Jun; 293(22):8656-8671. PubMed ID: 29666185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlations of Hepatic Hemodynamics, Liver Function, and Fibrosis Markers in Nonalcoholic Fatty Liver Disease: Comparison with Chronic Hepatitis Related to Hepatitis C Virus.
    Shigefuku R; Takahashi H; Nakano H; Watanabe T; Matsunaga K; Matsumoto N; Kato M; Morita R; Michikawa Y; Tamura T; Hiraishi T; Hattori N; Noguchi Y; Nakahara K; Ikeda H; Ishii T; Okuse C; Sase S; Itoh F; Suzuki M
    Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27649152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
    Pierantonelli I; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.